目的骨的原发性淋巴瘤虽然可以通过化疗和放疗得到有效控制,但复发的比率很高。本研究旨在分析和评价利妥昔单抗联合CHOP方案治疗CD20阳性骨原发性非何杰金淋巴瘤的临床疗效及其安全性。方法回顾11例利妥昔单抗联合CHOP方案治疗的骨原发性非何杰金淋巴瘤患者临床资料,利妥昔单抗用药方法为375mg/m~2,于每周期化疗前1d静脉滴注,每3周为1个循环周期;6～8个周期后评价疗效及不良反应,同时与单纯应用CHOP化疗的患者进行回顾性疗效分析比较。结果 11例患者接受利妥昔单抗联合CHOP方案化疗,完全缓解(CR)8例,部分缓解(PR)3例。随诊时间9-65个月,8例无瘤生存,1例转化为淋巴细胞型白血病,患者带瘤生存,2例死亡,患者生存率81.8%(9/11),无病生存率72.7%(8/11);Kaplan-Meier生存曲线计算应用利妥昔单抗的患者5年预期整体生存率(overall survival,OS)为60.6%。R-CHOP化疗后最常见的复发部位为中枢神经系统。不良反应与单纯应用CHOP化疗组无显著差异,主要为过敏和发热,以及化疗相关的血液学毒性,未出现爆发性肝衰竭。结论利妥昔单抗联合CHOP方案治疗骨原发性非何杰金淋巴瘤(CD20~+)效果显著,如何降低中枢神经系统复发是今后的研究方向。 The primary bone of primary lymphoma can be effectively controlled by chemotherapy and radiotherapy, but the recurrence rate is high. This study aimed to analyze and evaluate the clinical efficacy and safety of rituximab plus CHOP regimen in the treatment of CD20 positive non-Hodgkin’s lymphoma. Methods The clinical data of 11 patients with primary non-Hodgkin’s lymphoma treated with rituximab combined with CHOP regimen were retrospectively analyzed. Rituximab was given as 375 mg / m 2 intravenously Note, every 3 weeks for a cycle; 6 to 8 cycles after the evaluation of the efficacy and adverse reactions, while the simple application of CHOP chemotherapy in patients with retrospective analysis of efficacy and comparison. Results Eleven patients received rituximab combined with CHOP regimen. Eight patients were completely relieved (CR) and 3 patients were partially relieved (PR). The follow-up time ranged from 9 to 65 months. Eight patients had no tumor and one patient was transformed into lymphocytic leukemia. The patients survived with tumor and two died. The survival rate was 81.8% (9/11) and the disease-free survival rate was 72.7% (8/11); Kaplan-Meier survival curves calculated 5-year overall survival (OS) for patients on rituximab of 60.6%. The most common site of recurrence after R-CHOP chemotherapy is the central nervous system. Adverse reactions and simple application of CHOP chemotherapy group no significant differences, mainly allergic and fever, and chemotherapy-related hematologic toxicity, no occurrence of fulminant hepatic failure. Conclusion Rituximab combined with CHOP regimen has significant effect on the treatment of primary non-Hodgkin’s lymphoma (CD20 ~ +). How to reduce the CNS recurrence is the research direction in the future.